$53.10−0.02 (−0.04%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
MBX Biosciences (MBX) Institutional Ownership
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
Sources Ownership filingsQuarter ended How we compute thisNot investment advice
1 figure withheld by our checks. Each blank figure names its reason.
13F fund flowQuarter ended Sep 30, 2026*: more funds added or entered than trimmed or exited, mild accumulation (14 new · 29 increased · 9 reduced · 2 closed · 5 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 59 filers, Sep 30, 2026
# 13F FUNDS
59
13F VALUE
$187.8M
3.2M shares
Not reported in the company's filings for this period.
Insider trades · latest filings (Form 4)routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | Hoerter Steven L. | Chairman, President and CEO | Disposed · Open-market sale | 4,893 | $54.82 | ↗ |
| Nov 4, 2026 | Azoulay Salomon | Chief Medical Officer | Disposed · Open-market sale | 373 | $53.96 | ↗ |
| Oct 20, 2026 | Radovich Peter | director | Acquired · Grant / award | 18,200Stock option (right to buy) | — | ↗ |
| Aug 4, 2026 | Azoulay Salomon | Chief Medical Officer | Disposed · Open-market sale | 370 | $65.77 | ↗ |
| Aug 3, 2026 | Smither John W | Chief Financial Officer | Acquired · Grant / award | 28,000 | — | ↗ |
| Aug 3, 2026 | Smither John W | Chief Financial Officer | Acquired · Grant / award | 130,000Stock option (right to buy) | — | ↗ |
| Aug 3, 2026 | Hoerter Steven L. | President and CEO | Acquired · Grant / award | 71,000 | — | ↗ |
| Aug 3, 2026 | Hoerter Steven L. | President and CEO | Acquired · Grant / award | 331,000Stock option (right to buy) | — | ↗ |
| Jun 4, 2026 | Mathers Edward T | director | Acquired · Grant / award | 12,500Stock option (right to buy) | — | ↗ |
| Jun 4, 2026 | Pescovitz Ora H. | director | Acquired · Grant / award | 12,500Stock option (right to buy) | — | ↗ |
| Jun 4, 2026 | Heron Patrick J | director | Acquired · Grant / award | 12,500Stock option (right to buy) | — | ↗ |
| Jun 4, 2026 | Stelzer Laurie | director | Acquired · Grant / award | 12,500Stock option (right to buy) | — | ↗ |
| Jun 4, 2026 | Hoerter Steven L. | director | Acquired · Grant / award | 12,500Stock option (right to buy) | — | ↗ |
| Jun 4, 2026 | Ryder Steven | director | Acquired · Grant / award | 12,500Stock option (right to buy) | — | ↗ |
| Jun 4, 2026 | Aynechi Tiba | director | Acquired · Grant / award | 12,500Stock option (right to buy) | — | ↗ |
| May 8, 2026 | Azoulay Salomon | Chief Medical Officer | Acquired · Option exercise | 55,000 | $10.46 | ↗ |
| May 8, 2026 | Azoulay Salomon | Chief Medical Officer | Disposed · Open-market sale | 55,000 | $38.38 | ↗ |
| May 8, 2026 | Azoulay Salomon | Chief Medical Officer | Acquired · Option exercise | 15,003 | $16.00 | ↗ |
| May 8, 2026 | Azoulay Salomon | Chief Medical Officer | Disposed · Open-market sale | 15,003 | $38.30 | ↗ |
| May 8, 2026 | Azoulay Salomon | Chief Medical Officer | Acquired · Option exercise | 55,000Stock option (right to buy) | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How many 13F filers hold MBX Biosciences?
MBX Biosciences was held by 59 13F filers as of Sep 30, 2026.
Not investment advice.

